According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “
A number of other brokerages have also issued reports on ALBO. HC Wainwright raised their target price on Albireo Pharma from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, December 18th. Wedbush reissued a “buy” rating and issued a $66.00 target price on shares of Albireo Pharma in a research note on Thursday, November 19th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $64.25.
NASDAQ ALBO traded down $0.76 during trading hours on Wednesday, hitting $37.63. 7,804 shares of the company were exchanged, compared to its average volume of 187,399. The stock has a market cap of $717.87 million, a PE ratio of -6.13 and a beta of 1.62. The stock has a 50-day moving average price of $37.88 and a 200 day moving average price of $35.02. Albireo Pharma has a 52 week low of $11.26 and a 52 week high of $49.00. The company has a quick ratio of 13.51, a current ratio of 13.52 and a debt-to-equity ratio of 0.04.
Finding the right financial advisor to fit your needs doesn’t have to be hard. SmartAsset’s free quiz matches you with fiduciary financial advisors in your area in 5 minutes. Each advisor is legally bound to act in your best interest.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALBO. Pacer Advisors Inc. acquired a new position in Albireo Pharma during the 4th quarter worth $40,000. US Bancorp DE grew its position in Albireo Pharma by 1,786.1% during the third quarter. US Bancorp DE now owns 1,905 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,804 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Albireo Pharma in the third quarter valued at approximately $92,000. Citigroup Inc. lifted its stake in shares of Albireo Pharma by 435.5% in the fourth quarter. Citigroup Inc. now owns 3,454 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 2,809 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Albireo Pharma by 10.3% in the third quarter. JPMorgan Chase & Co. now owns 4,958 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 461 shares during the last quarter. 85.65% of the stock is owned by institutional investors and hedge funds.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Story: What is the Gross Domestic Product (GDP)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
The debate over renewable energy (i.e., clean energy) versus nonrenewable energy derived from fossil fuels was always going to come down to dollars and cents. Since 2016, things haven’t been easy for renewable energy companies. As the United States pushed towards energy independence, the Trump administration imposed tariffs on the industrial segments. The sector was subject to less favorable policies by electricity regulators. Plus, competing energy sources like coal received more help.
But a funny thing happened over the past four years. Renewable energy companies continued to grow. This is continuing a pattern that renewable sources of energy are becoming cost-competitive for businesses. And that is increasing demand.
One of the best parts of this sector for investors is that there are many ways to play the sector. In addition to solar and wind, hydrogen stocks are becoming an intriguing way to invest in renewable energy.
So rather than looking at this election as a choice between bad and good, investors should really be viewing it as a case of “good or better.” Because no matter who wins the election, clean energy stocks will continue to grow.